Abstract

The objective: to evaluate the effect of Tivor-L (20 mg levocarnitine + 42 mg arginine hydrochloride, Yuriya-Pharm) on AGEs, galectin-3, MMP-2,9 serum level, cardiac haemodynamics and endothelial function in patients with post infarction HFpEF.Materials and methods. All individuals (35) included aged 40 to 80 years, 23 (66%) males and 12 (34%) females were diagnosed with (HFpEF) according to ESC guidelines (2016). First (1-st ) group (n=15) pts with postinfarction HFpEF treated with Tivor-L in addition to standard treatment for Chronic heart failure (CHF). Second (2nd) group (n=20) – pts with postinfarction HFpEF with standard treatment for CHF without Tivor-L. All the patients included in 1st group got Tivor-L intravenously daily for 10 days in addition to the conventional therapy. General biochemical blood analysis, complete blood count and glomerular filtration rate, MMP-2, MMP-9, galectin-3 and AGEs serum levels were determined before and after treatment.Results. Mean galectin-3 level in 1st was decreased by 16.4 % on the whole (p<0,05), in compare with standard therapy – no significant changes (p>0,05). significant decreasing of MMP-2, MMP-9 levels on 41% and 78,5% in 1st group (p<0,05). The FMD level was significantly higher in 1st group than in standard therapy group (p<0,05). Endothelial function normalizing was achieved in 10 (66%) of 1st group patients.Conclusion. Most of the pts with postinfarction HFpEF have increased AGEs serum level, and endothelial dysfunction. There were a significant decrease in galectin-3 and MMP-2, MMP-9 serum levels after adding of Tivor-L to the conventional treatment for chronic heart failure.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.